Dr. Reddy's Laboratories · risk themes across the available quarters.
Bear-case history
Root cause analysis complete with 80-90% confidence of resolution by September 23, but API re-validation could fail, delaying November supply resumption and impacting 6-7 million pen opportunity and potential PLA incentives.
USFDA issued 7 observations at Bachupalli biologics facility (PLI completed June 2026); while all observations deemed addressable and responses submitted, additional GMP queries or clinical data requests could delay December 2026 PDUFA goal date.
CEO explicitly admitted R&D productivity failures in certain complex generics (iron sucrose, conjugated estrogen, peptides) over past 4-5 years, though believes corrections were made—products in development now reflect 10-12 year lead times.
US President announced potential tariffs on generics; while management downplayed immediate impact citing 2-year runway and 25-30% US manufacturing already via CMO, concrete mitigation strategy remains undefined beyond monitoring IPA/industry association engagement.
USFDA issued a post-action letter for observations at the Bachupally biologics facility, potentially delaying rituximab and denosumab approvals.
Management advised assuming zero lenalidomide revenue from Q4 FY26, which will impact overall revenue and margins.
Management acknowledged that semaglutide pricing may be at the lower end of the $20-70 range due to competition, including Novo Nordisk's own generic.
CRL for denosumab from Alvotech facility may push US approval to Q2 FY27 or later, impacting biosimilar revenue expectations.